{"title":"[Current status and trends of perioperative immunotherapy for gastric cancer].","authors":"Y F Zhu, J K Hu","doi":"10.3760/cma.j.cn112139-20250315-00132","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years,immunotherapy,particularly immune checkpoint inhibitors,has been widely used in the treatment of both solid and non-solid tumors,and it has become an important component of comprehensive gastric cancer treatment. The clinical application of immunotherapy in gastric cancer has gradually expanded from first-line treatment for advanced gastric cancer to perioperative treatment for resectable locally advanced gastric cancer. The use of immunotherapy combined with chemotherapy,targeted therapy,and other treatment modalities in the perioperative management of gastric cancer has injected new vitality into perioperative treatment strategies,establishing a novel model for comprehensive perioperative gastric cancer treatment. However,the application of immunotherapy in gastric cancer treatment still faces challenges such as limited high-level evidence for perioperative use,drug resistance,and adverse effects. In the future,efforts should focus on conducting high-level evidence-based clinical research on perioperative immunotherapy for gastric cancer,exploring and optimizing combined immunotherapy regimens,and delving into the molecular biological mechanisms of the tumor immune microenvironment in gastric cancer. By leveraging artificial intelligence and big data platform technologies,further optimization of screening strategies for potential beneficiaries should be pursued,and personalized precision treatment should be employed to address and overcome the challenges faced by immunotherapy in gastric cancer.</p>","PeriodicalId":60685,"journal":{"name":"中华外科杂志","volume":"63 7","pages":"575-580"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华外科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112139-20250315-00132","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
In recent years,immunotherapy,particularly immune checkpoint inhibitors,has been widely used in the treatment of both solid and non-solid tumors,and it has become an important component of comprehensive gastric cancer treatment. The clinical application of immunotherapy in gastric cancer has gradually expanded from first-line treatment for advanced gastric cancer to perioperative treatment for resectable locally advanced gastric cancer. The use of immunotherapy combined with chemotherapy,targeted therapy,and other treatment modalities in the perioperative management of gastric cancer has injected new vitality into perioperative treatment strategies,establishing a novel model for comprehensive perioperative gastric cancer treatment. However,the application of immunotherapy in gastric cancer treatment still faces challenges such as limited high-level evidence for perioperative use,drug resistance,and adverse effects. In the future,efforts should focus on conducting high-level evidence-based clinical research on perioperative immunotherapy for gastric cancer,exploring and optimizing combined immunotherapy regimens,and delving into the molecular biological mechanisms of the tumor immune microenvironment in gastric cancer. By leveraging artificial intelligence and big data platform technologies,further optimization of screening strategies for potential beneficiaries should be pursued,and personalized precision treatment should be employed to address and overcome the challenges faced by immunotherapy in gastric cancer.
期刊介绍：
Chinese Journal of Surgery|Chin J Surg (monthly) is a high-level medical science and technology journal approved by the General Administration of Press and Publication of the People's Republic of China, under the supervision of the China Association for Science and Technology, and organised by the Chinese Medical Association for domestic and international public circulation. It was founded in January 1951, and is published on the basis of the Journal of Chinese Surgery. The Journal is aimed at senior and intermediate surgeons and related researchers, mainly reporting the leading scientific research results and clinical experience in the field of surgery, as well as the basic theoretical research that has a guiding effect on the clinical work of surgery.
Chinese Journal of Surgery|Chin J Surg is committed to reflecting the major research progress in the field of surgery in China and promoting academic exchanges at home and abroad. The main columns include thesis, meta-analysis, review, expert forum, synthesis, case report, diagnosis and treatment experience, technical exchange, clinical case discussion, academic controversy, and special lectures, etc. The journal has been accepted by the National Academy of Medicine of the United States. The journal has been included in many famous databases at home and abroad, such as the Biomedical Analysis and Online Retrieval System (MEDLINE) of the U.S. National Library of Medicine.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
